[HTML][HTML] Vasopressin in chronic kidney disease: an elephant in the room?
VE Torres - Kidney international, 2009 - Elsevier
VE Torres
Kidney international, 2009•ElsevierPerico et al. report that a dual arginine vasopressin (AVP) V 2 and V 1a receptor antagonist
lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats,
pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely
contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and
mesangial and/or epithelial cells, but the relative contributions of V 2 and V 1a receptors and
potential usefulness of V 2 and V 1a receptor antagonists remain ill defined.
lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats,
pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely
contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and
mesangial and/or epithelial cells, but the relative contributions of V 2 and V 1a receptors and
potential usefulness of V 2 and V 1a receptor antagonists remain ill defined.
Perico et al. report that a dual arginine vasopressin (AVP) V2 and V1a receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V2 and V1a receptors and potential usefulness of V2 and V1a receptor antagonists remain ill defined.
Elsevier
